Zubsolv tablets market share week 20 reached 6.07%, up 0.02 percentage points from last week according to Wolters Kluwers latest data released today. The rolling four week average were unchanged at 6.06%. TRx were slightly lower reaching a market share of 5.55% and the rolling four week average market share were 5.52%. Monthly buprenorphine/naloxone unit sales showed a y/y growth rate of 8.6%, which were 0.3 percentage points lower than last week. TRx showed a y/y growth rate of 4.8%, representing a decrease of 0.1 percentage points from last week. This week’s numbers show very small w/w changes in market shares between the products.